| Literature DB >> 32911639 |
K V Surangi Dharmawansa1, David W Hoskin2,3, H P Vasantha Rupasinghe1,2.
Abstract
Anthocyanins are a group of dietary polyphenols, abundant mainly in fruits and their products. Dietary interventions of anthocyanins are being studied extensively related to the prevention of gastrointestinal (GI) cancer, among many other chronic disorders. This review summarizes the hereditary and non-hereditary characteristics of GI cancers, chemistry, and bioavailability of anthocyanins, and the most recent findings of anthocyanin in GI cancer prevention through modulating cellular signaling pathways. GI cancer-preventive attributes of anthocyanins are primarily due to their antioxidative, anti-inflammatory, and anti-proliferative properties, and their ability to regulate gene expression and metabolic pathways, as well as induce the apoptosis of cancer cells.Entities:
Keywords: bioavailability; chemoprevention; gastrointestinal tract; inflammation; molecular mechanisms; polyphenols
Mesh:
Substances:
Year: 2020 PMID: 32911639 PMCID: PMC7554903 DOI: 10.3390/ijms21186555
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Two-hit theory of the initiation of hereditary and non-hereditary cancer. People with a hereditary susceptibility to GI cancers harbor an inherited genetic mutation on one of the chromosomes at the time of conception and receive the 1st somatic mutation due to the endogenous (e.g., chronic inflammation) or exogenous (e.g., exposure to carcinogens) rare events which in turn inactivate the full function of the respective gene and initiate neoplastic transformation. Non-inherited forms of GI cancer occur by acquiring two somatic mutations in later life, resulting in the inactivation of a gene leading to the initiation of malignancy.
Hereditary basis of GI cancers.
| Type of the Cancer | Syndrome | Associated Germline Mutations | Reference | |
|---|---|---|---|---|
|
| Familial Barrett’s esophagus, Familial esophageal adenocarcinoma | MSR1, ASCC1 and CTHRC1 | [ | |
| Tylosis with esophageal cancer-squamous cell carcinoma | RHBDF2 | [ | ||
|
| Diffuse hereditary gastric cancer-adenocarcinoma | CDH1 (E-cadherin) | [ | |
|
| Hereditary pancreatitis | PRSS1, CFTR, SPINK1, CTRC | [ | |
| Hereditary breast and ovarian cancer | BRCA1/2 | |||
| Peutz-Jeghers syndrome | STK11/LKB1 | |||
| Familial atypical multiple | CDKN2A/p16 | |||
| Familial adenomatous polyposis | APC | |||
|
| Familial adenomatous polyposis | APC | [ | |
| Lynch syndrome | EPCAM, MLH1, MSH2, MSH6, PMS2 | |||
| MYH associated polyposis | MUTYH | |||
| Hamartomatous polyposis syndrome | Peutz-Jeghers syndrome | STK11 | ||
| Juvenile polyposis syndrome | SMAD4, BMPR1A | |||
| Attenuated Familial adenomatous polyposis | APC | |||
|
| Familial adenomatous polyposis | APC | [ | |
| Lynch syndrome | Mutations in mismatch repair genes | |||
| Juvenile polyposis syndrome | SMAD4 | |||
| Peutz-Jeghers syndrome | STK11 | |||
|
| α-1 antitrypsin deficiency | SERPINA1 | [ | |
| Hereditary hemochromatosis | HFE | |||
| Hereditary tyrosinemia type 1 | FAH | |||
| Glycogen storage disease type 1 | G6PC, SLC37A4 | |||
| Wilson’s disease | ATP7B | |||
| Niemann-park disease | SMPD1 AND NPC1 OR NPC2 | |||
|
| Bile salt export pump deficiency | ABCB11 | [ | |
Figure 2Major anthocyanins derived from the basic anthocyanin structure. Based on the changes in R1 and R2 chemical groups, six major anthocyanins have been identified.
Figure 3The possible anticarcinogenic mechanisms of anthocyanins in GI cancer prevention. Anthocyanins inhibit the pro-inflammatory COX-2 and NF-κB pathways and inhibit cell proliferation via reducing the nuclear translocation of β-catenin, upregulating cyclin-dependent kinase inhibitors, and downregulating cyclin proteins. Anthocyanins reduce the degradation of components of the extracellular matrix by suppressing the activity of MMPs and tight junction (TJ) proteins. Anthocyanins act as topoisomerase inhibitors and stimulate the DNA strand break response, leading to apoptosis. Anthocyanins induce apoptosis via the mitochondrial pathway and activation of caspase-9. Anthocyanins modulate gut microbial dysbiosis, hence reducing the production of ROS in macrophages and suppressing chronic inflammation. P21, P27, P53, cyclin-dependent kinase inhibitors; COX-2, cyclooxygenase-2; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; MMP-2 and 9, matrix metalloproteinases 2 and 9; ROS, reactive oxygen species. Blue upwards arrow, promote; orange downwards arrow, inhibit.
Evidence that anthocyanins have chemopreventive properties against GI cancer and their potential cellular mechanisms.
| Source of Anthocyanin | Dosage | Cell Line/Animal Model | Observations | Reference |
|---|---|---|---|---|
|
| ||||
|
| 50 µg/mL | Human oral SCC131 cells | Reduced STAT-3 phosphorylation and nuclear translocation | [ |
|
| 25–200 µg/mL | Human oral epidermal KB, CAL-27 cancer cells | Inhibited cell proliferation | [ |
|
| 100–500 µg/mL | Human tongue epithelial CAL 27 cells | Inhibited cell migration and invasion | [ |
|
| 250 µg/mL | Human oral SCC | Reduced cell viability, Inhibited migration, and invasion abilities | [ |
|
| 2.5 mg/kg of body weight | Male Wistar rats; 4-nitroquinoline 1-oxide induced tongue carcinogenesis | Reduced epithelial dysplasia | [ |
|
| 5% or 10% | Hamster cheek pouch (HCP) model of oral cancer | Reduced number of tumors | [ |
|
| ||||
|
| 100 μg/mL | Human esophageal microvascular endothelial cells (HEMEC) | Inhibited TNF-α/IL-1β-induced NFκB p65 nuclear translocation, PGE2 production | [ |
|
| 10–50 µg/mL | RE-149DHD and RE-149 rat esophageal cancer cell lines | Inhibited cell growth | [ |
|
| 2.5% | Male Sprague-Dawley rats, EDA surgery-induced carcinogenesis | No change in COX-2 level | [ |
|
| 5% | NMBA-induced carcinogenesis in F344 rats | Influenced the metabolic activation and detoxification of NMBA | [ |
|
| 5% | NMBA induced carcinogenesis in F344 rats | Reduced NF-κB protein expression | [ |
|
| 5% | NMBA induced carcinogenesis in F344 rats | Reduced serum cytokines, IL-5, and GRO/KC protein expression | [ |
|
| 6.1% | NMBA induced carcinogenesis in F344 rats | Reduced IL-1β protein expression | [ |
|
| ||||
|
| 50–200 µg/mL | Human AGS cells | Induced apoptosis-arrest G0/G1 phase | [ |
|
| 12.5–50 µg/mL | Reduced | [ | |
|
| ||||
|
| 100, 500 mg/kg body weight for 22 weeks | DENA-induced carcinogenesis in rats | Reduced abnormal lipid peroxidation, protein oxidation and expression of iNOS, 3-nitrotyrosine, Nrf-2 | [ |
|
| 50–200 µg/mL | Human HepG2 cells | Reduced P-AKT level, MMP-2 and, MMP-9 protein expression | [ |
|
| 400 µg/mL | Human Hep3B cells | Reduced MMP-2, MMP-9 protein expression | [ |
|
| 100 or 500 µg/mL | Rat hepatoma cells (MH1C1)-DNA damaged induced by TBHP | Reduced DNA single-strand formation and lipid peroxidation | [ |
|
| 400 µg/mL | Human Hep3B cells | Reduced cell proliferation, invasion | [ |
|
| 0.001–0.1 mg/mL | Human HCC cell lines PLC/PRF/5 | Increased Bax, cytochrome c, caspase 3 and, elF2-α protein expression | [ |
|
| 100 µg/mL | Human HepG2 cells | Reduced cell growth | [ |
|
| 0.125%, 0.625% | DENA-induced carcinogenesis in Sprague-Dawley rats | Increased incidence, total number, multiplicity, size, and volume of preneoplastic hepatic nodules | [ |
|
| ||||
|
| 10–100 µmol/L | Human Caco-2 cells | Reduced cell viability | [ |
|
| 50–500 μg/mL | Human Caco-2 cells | Inhibited cell proliferation | [ |
|
| 70–100 μg/mL | Human HT-29 | Inhibited cell proliferation | [ |
|
| 0%, 2.5%, 5%, or 10% wt/wt for 33 weeks | AOM-induced carcinogenesis in F344 rats | Reduced ACF, tumor multiplicity, adenocarcinoma multiplicity by the dose-depended manner | [ |
|
| 10% | C57BL/6J-APCMIN/+ mice | Reduced adenoma number (0.12% | [ |
|
| 5% | APCMIN/+ mice | Reduced intestinal and colonic polyp number and size | [ |
|
| 1 to 20 μg/mL | TNF-α stimulated Human HT-29 cells, CCD-18Co non-malignant colonic fibroblasts | Inhibited cell proliferation | [ |
|
| 0–40 μM | Human colonic SW480 cancer cells | Inhibited cell proliferation | [ |
|
| 10–30 μg/mL | Human HCT-116 and HT-29 cells | Inhibited cell proliferation | [ |
|
| 0–50 µM | TNF-α stimulated Human HCT116, HT29, and SW620 | Suppressed NF-κB signaling | [ |
|
| 0.5,5,25 μg/mL | Human HCT116, Caco2 and SW480 cells | Increased protein expression of DNMT1 and DNMT3B | [ |
|
| 0–40 μg/mL | Human HT-29 cells | Inhibited cell proliferation | [ |
|
| 3.85 g/kg for 4 weeks | AOM-induced carcinogenesis in F344 rats | Reduced ACF, fecal bile acids and, colonic cellular proliferation | [ |
|
| 10% | AOM/DSS-induced colitis-associated carcinogenesis in Balb/c mice | Less reduced colon length | [ |
Abbreviations used: AKT, protein kinase B; AP-1, activator protein 1; bcl-2, B-cell lymphoma 2; BAX, Bcl-2 associated X; COX-2, cyclooxygenase 2; CIAP-1, cellular inhibitor of apoptosis protein-1; CIAP-2, cellular inhibitor of apoptosis protein-2; DNMT1, DNA (cytosine-5)-methyltransferase 1; DNMT2, DNA (cytosine-5)-methyltransferase 2; elF2-α, eukaryotic initiation factor 2; ERK, extracellular-signal-regulated kinase; GRO/KC, growth related oncogene; CXCL1; IL-4,5,10,12,13,1β, Interleukin-4,5,10,12,13,1β; IFN-γ, interferon γ; iNOS, inducible nitrogen oxide synthase; JAK, Janus kinase; LC3-I, LC3-I, microtubule-associated protein light chain 3; MMP-2,9, matrix metalloproteinase-2,9; MAPK, mitogen-activated protein kinase; MnSOD, manganese superoxide dismutase; MyD88, myeloid differentiation primary response 88; MTOR, mammalian target of rapamycin; NLRP3, NLR family pyrin domain containing 3; NMBA, N-nitroso methylbenzylamine; NF-κB, Nuclear factor κ-light-chain-enhancer of activated B cells; OCT-1, Octamer proteins in humans; PI3K, phosphoinositide 3-kinases; P-NF-κB, phosphorylated nuclear factor κ-light-chain-enhancer of activated B cells; ROS, reactive oxygen species; STAT-1,3, signal transducer and activator of transcription 1,3; XIAP, X-linked inhibitor of apoptosis protein.
Experimental findings on the effect of anthocyanin-supplementation on the DSS-induced colitis in experimental animals.
| Source of Anthocyanin | Dosage | Treatment | Observations | Reference |
|---|---|---|---|---|
|
| 25, 50, and 100 mg/kg of body weight | 8 weeks old female C57BL/6 mice: administration of 3% DSS for 5 consecutive days in drinking water | Reduced DAI and the histological score of colons, myeloperoxidase (MPO) and nitric oxide (NO) levels and, mRNA expression of IL-6, IL-1β, TNF-α, iNOS, and COX-2 | [ |
|
| 24 mg/kg of feed weight | 4–5 weeks old C57BL/6J male mice: 2 cycles (7 days of 2.5% DSS and 14 days of fresh tap water) | Improved histopathological scores | [ |
|
| 50 mg/kg body weight | Female Balb/C mice: administration of 3% DSS for 1 week in drinking water | Reduced DAI and improved the macroscopic and histological score of colons | [ |
|
| 5% | Six-week-old male C57BL/6J mice: administration of 2 repeated cycles of 1% DSS (7-d DSS treatment plus 14-d recovery) | Reduced DAI score and histologic damage | [ |
|
| 50–200 mg/kg of body weight | 6 weeks old | Reduced protein expression of COX2 and IL-6 in LPS-stimulated RAW 264.7 cells | [ |
|
| 50 mg/kg of body weight | C57BL/6 mice: administration of 3% DSS for 8 days in drinking water | Reduced DAI score and histologic damage | [ |
|
| 1.5% | 6 weeks old male CD-1 mice: 1.5% DSS for 4 cycles (4 days/cycle, with a 7-day | Inhibited reduction in colon length | [ |
|
| 10% | Balb/c mice: 2.5% DSS for 1 week in drinking water | Reduced DAI and histologic score | [ |
|
| Intraperitoneal injected with 1ug C3G every 2 days, a total of 3 times | 8–12 weeks old C57BL/6 mice: 3.5% DSS for 1 week in drinking water | No change in body weight and colon length | [ |
|
| 0.13 or 0.16 mg/day by gavage | 5 weeks old female ICR mice: 3% DSS for 2 weeks in drinking water | Lowered body weight loss, spleen hypertrophy, and shortening of the colon | [ |
|
| 5% | 6–7 weeks old C57BL/6 mice: 2% DSS for 1 week in drinking water | Reduced DSS-induced colon shortening and inflammatory cell infiltration | [ |
Abbreviations used: CCL22, C-C motif chemokine ligand 22; COX-2, cyclooxygenase 2; DAI, disease activity index; IL-6, 1β, interleukin-6, 1β; IFN-γ, interferon-γ; iNOS, inducible nitrogen oxide synthase; MDA, malondialdehyde; MPO, myeloperoxidase; NO, nitrogen oxide; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; STAT-3, signal transducer and activator of transcription 3; TNL-α, tumor necrosis factor-α.